Logo image of ISO

ISOPLEXIS CORP (ISO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ISO - US4650051067 - Common Stock

0.7616 USD
+0.02 (+2.78%)
Last: 3/20/2023, 8:17:18 PM
Fundamental Rating

2

ISO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. ISO may be in some trouble as it scores bad on both profitability and health. ISO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ISO has reported negative net income.
ISO had a negative operating cash flow in the past year.
ISO Yearly Net Income VS EBIT VS OCF VS FCFISO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for ISO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISO Yearly ROA, ROE, ROICISO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ISO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISO Yearly Profit, Operating, Gross MarginsISO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -200 -400 -600

2

2. Health

2.1 Basic Checks

ISO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ISO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ISO has a worse debt to assets ratio.
ISO Yearly Shares OutstandingISO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
ISO Yearly Total Debt VS Total AssetsISO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.00, we must say that ISO is in the distress zone and has some risk of bankruptcy.
ISO has a Altman-Z score of -5.00. This is amonst the worse of the industry: ISO underperforms 90.63% of its industry peers.
A Debt/Equity ratio of 1.12 is on the high side and indicates that ISO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.12, ISO is doing worse than 82.81% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF N/A
Altman-Z -5
ROIC/WACCN/A
WACC12.77%
ISO Yearly LT Debt VS Equity VS FCFISO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 4.06 indicates that ISO has no problem at all paying its short term obligations.
ISO has a Current ratio of 4.06. This is comparable to the rest of the industry: ISO outperforms 53.13% of its industry peers.
A Quick Ratio of 2.50 indicates that ISO has no problem at all paying its short term obligations.
ISO's Quick ratio of 2.50 is in line compared to the rest of the industry. ISO outperforms 40.63% of its industry peers.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 2.5
ISO Yearly Current Assets VS Current LiabilitesISO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M

6

3. Growth

3.1 Past

The earnings per share for ISO have decreased strongly by -14.08% in the last year.
Looking at the last year, ISO shows a decrease in Revenue. The Revenue has decreased by -2.88% in the last year.
ISO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.71% yearly.
EPS 1Y (TTM)-14.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.42%
Revenue 1Y (TTM)-2.88%
Revenue growth 3Y30.71%
Revenue growth 5YN/A
Sales Q2Q%-39.35%

3.2 Future

Based on estimates for the next years, ISO will show a very strong growth in Earnings Per Share. The EPS will grow by 24.09% on average per year.
Based on estimates for the next years, ISO will show a very strong growth in Revenue. The Revenue will grow by 55.04% on average per year.
EPS Next Y48%
EPS Next 2Y24.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.37%
Revenue Next 2Y56.88%
Revenue Next 3Y55.04%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ISO Yearly Revenue VS EstimatesISO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ISO Yearly EPS VS EstimatesISO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 -1 -2 -3

1

4. Valuation

4.1 Price/Earnings Ratio

ISO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ISO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISO Price Earnings VS Forward Price EarningsISO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISO Per share dataISO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ISO's earnings are expected to grow with 24.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.09%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ISO!.
Industry RankSector Rank
Dividend Yield N/A

ISOPLEXIS CORP

NASDAQ:ISO (3/20/2023, 8:17:18 PM)

0.7616

+0.02 (+2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-02 2023-03-02/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner Change0%
Market Cap30.21M
Revenue(TTM)16.76M
Net Income(TTM)-106.00M
Analysts46.67
Price Target1.63 (114.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-61.16%
Min EPS beat(2)-113.25%
Max EPS beat(2)-9.06%
EPS beat(4)0
Avg EPS beat(4)-41.24%
Min EPS beat(4)-113.25%
Max EPS beat(4)-9.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.05%
Min Revenue beat(2)-42%
Max Revenue beat(2)-4.11%
Revenue beat(4)1
Avg Revenue beat(4)-15.53%
Min Revenue beat(4)-42%
Max Revenue beat(4)9.55%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.58%
EPS NY rev (3m)-2.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.55%
Revenue NY rev (1m)5.36%
Revenue NY rev (3m)5.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.8
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.42
BVpS1.04
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 221.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.06
Quick Ratio 2.5
Altman-Z -5
F-Score2
WACC12.77%
ROIC/WACCN/A
Cap/Depr(3y)510.76%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.42%
EPS Next Y48%
EPS Next 2Y24.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.88%
Revenue growth 3Y30.71%
Revenue growth 5YN/A
Sales Q2Q%-39.35%
Revenue Next Year49.37%
Revenue Next 2Y56.88%
Revenue Next 3Y55.04%
Revenue Next 5YN/A
EBIT growth 1Y-27.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.89%
EBIT Next 3Y21.07%
EBIT Next 5YN/A
FCF growth 1Y5.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.72%
OCF growth 3YN/A
OCF growth 5YN/A

ISOPLEXIS CORP / ISO FAQ

What is the fundamental rating for ISO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ISO.


Can you provide the valuation status for ISOPLEXIS CORP?

ChartMill assigns a valuation rating of 3 / 10 to ISOPLEXIS CORP (ISO). This can be considered as Overvalued.


Can you provide the profitability details for ISOPLEXIS CORP?

ISOPLEXIS CORP (ISO) has a profitability rating of 0 / 10.